How complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression?-future perspectives
- PMID: 30997178
- PMCID: PMC6424798
- DOI: 10.21037/jtd.2019.02.21
How complement activation via a C3a receptor pathway alters CD4+ T lymphocytes and mediates lung cancer progression?-future perspectives
Conflict of interest statement
Conflicts of Interest: Dr. M Magalhães Filho has no disclosures. Dr. PN Aguiar Junior reports speaker fees from MERCK CO, outside the submitted work. Mr. JJ Adashek has no disclosures. RA De Mello: advisory board consultant for Zodiac, MSD, Pfizer. Speaker fee from Astrazenenca, Novartis. Honoraria from National Medical Research Council, Singapure, and National Science Centre, Krakow, Poland.
Comment on
-
Complement Activation via a C3a Receptor Pathway Alters CD4+ T Lymphocytes and Mediates Lung Cancer Progression.Cancer Res. 2018 Jan 1;78(1):143-156. doi: 10.1158/0008-5472.CAN-17-0240. Epub 2017 Nov 8. Cancer Res. 2018. PMID: 29118090 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Research Materials